Baird Reiterates an 'Outperform' on Alexion Pharmaceuticals (ALXN); Raising N-T Estimates Ahead of Qtr

Article Stock Quotes (1) Comments (0)

Baird reiterates an 'Outperform' on Alexion Pharmaceuticals (NASDAQ: ALXN) price target of $110.00 (from $100.00).

Analyst, Christopher Raymond, said, "While management provided detailed color around Q212 last quarter, we think the operational flexibility of this business model, coupled with real revenue upside potential from the ongoing Soliris aHUS launch can make for yet another quarterly beat. As such, we are raising our Q212 EPS estimate to $0.38 from $0.35...Despite a higher-than-average valuation, we think this name can continue to work higher."

For an analyst ratings summary and ratings history on Alexion Pharmaceuticals click here. For more ratings news on Alexion Pharmaceuticals click here.

Shares of Alexion Pharmaceuticals closed at $97.19 yesterday, with a 52 week range of $46.56-$104.38.

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• UPDATE: Wedbush Downgrades XenoPort (XNPT) to Neutral
• Goldman Sachs Downgrades Thoratec (THOR) to Neutral
• Goldman Sachs Upgrades WNS (Holdings) (WNS) to Buy

Create E-mail Alert Related Categories

Analyst Comments, Analyst EPS Change, Analyst EPS View, Analyst PT Change

Related Entities

Robert W Baird

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?